These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
398 related articles for article (PubMed ID: 33421217)
1. Pathogenicity assessment of variants for breast cancer susceptibility genes based on BRCAness of tumor sample. Yoshida R; Hagio T; Kaneyasu T; Gotoh O; Osako T; Tanaka N; Amino S; Yaguchi N; Nakashima E; Kitagawa D; Ueno T; Ohno S; Nakajima T; Nakamura S; Miki Y; Hirota T; Takahashi S; Matsuura M; Noda T; Mori S Cancer Sci; 2021 Mar; 112(3):1310-1319. PubMed ID: 33421217 [TBL] [Abstract][Full Text] [Related]
2. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers. Cragun D; Weidner A; Tezak A; Clouse K; Pal T Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176 [TBL] [Abstract][Full Text] [Related]
4. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer. Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of pathogenetic mutations in breast cancer predisposition genes in population-based studies conducted among Chinese women. Zeng C; Guo X; Wen W; Shi J; Long J; Cai Q; Shu XO; Xiang Y; Zheng W Breast Cancer Res Treat; 2020 Jun; 181(2):465-473. PubMed ID: 32318955 [TBL] [Abstract][Full Text] [Related]
6. Prevalence of BRCA1, BRCA2, and PALB2 genomic alterations among 924 Taiwanese breast cancer assays with tumor-only targeted sequencing: extended data analysis from the VGH-TAYLOR study. Cheng HF; Tsai YF; Liu CY; Hsu CY; Lien PJ; Lin YS; Chao TC; Lai JI; Feng CJ; Chen YJ; Chen BF; Chiu JH; Tseng LM; Huang CC Breast Cancer Res; 2023 Dec; 25(1):152. PubMed ID: 38098088 [TBL] [Abstract][Full Text] [Related]
7. Comparison of BRCA versus non-BRCA germline mutations and associated somatic mutation profiles in patients with unselected breast cancer. Chen B; Zhang G; Li X; Ren C; Wang Y; Li K; Mok H; Cao L; Wen L; Jia M; Li C; Guo L; Wei G; Lin J; Li Y; Zhang Y; Han-Zhang H; Liu J; Lizaso A; Liao N Aging (Albany NY); 2020 Feb; 12(4):3140-3155. PubMed ID: 32091409 [TBL] [Abstract][Full Text] [Related]
8. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals. Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067 [TBL] [Abstract][Full Text] [Related]
9. Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in Yadav S; Boddicker NJ; Na J; Polley EC; Hu C; Hart SN; Gnanaolivu RD; Larson N; Holtegaard S; Huang H; Dunn CA; Teras LR; Patel AV; Lacey JV; Neuhausen SL; Martinez E; Haiman C; Chen F; Ruddy KJ; Olson JE; John EM; Kurian AW; Sandler DP; O'Brien KM; Taylor JA; Weinberg CR; Anton-Culver H; Ziogas A; Zirpoli G; Goldgar DE; Palmer JR; Domchek SM; Weitzel JN; Nathanson KL; Kraft P; Couch FJ J Clin Oncol; 2023 Mar; 41(9):1703-1713. PubMed ID: 36623243 [TBL] [Abstract][Full Text] [Related]
10. Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes. Gallagher S; Hughes E; Wagner S; Tshiaba P; Rosenthal E; Roa BB; Kurian AW; Domchek SM; Garber J; Lancaster J; Weitzel JN; Gutin A; Lanchbury JS; Robson M JAMA Netw Open; 2020 Jul; 3(7):e208501. PubMed ID: 32609350 [TBL] [Abstract][Full Text] [Related]
11. Simple prediction model for homologous recombination deficiency in breast cancers in adolescents and young adults. Watanabe T; Honda T; Totsuka H; Yoshida M; Tanioka M; Shiraishi K; Shimada Y; Arai E; Ushiama M; Tamura K; Yoshida T; Kanai Y; Kohno T Breast Cancer Res Treat; 2020 Jul; 182(2):491-502. PubMed ID: 32488393 [TBL] [Abstract][Full Text] [Related]
12. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer. Couch FJ; Shimelis H; Hu C; Hart SN; Polley EC; Na J; Hallberg E; Moore R; Thomas A; Lilyquist J; Feng B; McFarland R; Pesaran T; Huether R; LaDuca H; Chao EC; Goldgar DE; Dolinsky JS JAMA Oncol; 2017 Sep; 3(9):1190-1196. PubMed ID: 28418444 [TBL] [Abstract][Full Text] [Related]
13. Mainstream Model of Genetic Testing for Prostate Cancer at a Large Tertiary Cancer Centre. Wang X; Waldman L; Silberman Y; Wang M; Tackey C; Hanna L; Vesprini D; Emmenegger U; Eisen A; Smoragiewicz M Clin Genitourin Cancer; 2024 Jun; 22(3):102052. PubMed ID: 38461085 [TBL] [Abstract][Full Text] [Related]
14. Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic. Riedlova P; Janoutova J; Hermanova B Mol Biol Rep; 2020 Apr; 47(4):2763-2769. PubMed ID: 32180084 [TBL] [Abstract][Full Text] [Related]
16. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer. Kapoor NS; Curcio LD; Blakemore CA; Bremner AK; McFarland RE; West JG; Banks KC Ann Surg Oncol; 2015 Oct; 22(10):3282-8. PubMed ID: 26219241 [TBL] [Abstract][Full Text] [Related]
17. Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity. Pinto P; Paulo P; Santos C; Rocha P; Pinto C; Veiga I; Pinheiro M; Peixoto A; Teixeira MR Breast Cancer Res Treat; 2016 Sep; 159(2):245-56. PubMed ID: 27553368 [TBL] [Abstract][Full Text] [Related]
18. Germline mutations of breast cancer susceptibility genes through expanded genetic analysis in unselected Colombian patients. Sierra-Díaz DC; Morel A; Fonseca-Mendoza DJ; Bravo NC; Molano-Gonzalez N; Borras M; Munevar I; Lema M; Idrobo H; Trujillo D; Serrano N; Orduz AI; Lopera D; González J; Rojas G; Londono-De Los Ríos P; Manneh R; Cabrera R; Rubiano W; de la Peña J; Quintero MC; Mantilla W; Restrepo CM Hum Genomics; 2024 Jun; 18(1):68. PubMed ID: 38890714 [TBL] [Abstract][Full Text] [Related]
19. Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers. Renault AL; Mebirouk N; Fuhrmann L; Bataillon G; Cavaciuti E; Le Gal D; Girard E; Popova T; La Rosa P; Beauvallet J; Eon-Marchais S; Dondon MG; d'Enghien CD; Laugé A; Chemlali W; Raynal V; Labbé M; Bièche I; Baulande S; Bay JO; Berthet P; Caron O; Buecher B; Faivre L; Fresnay M; Gauthier-Villars M; Gesta P; Janin N; Lejeune S; Maugard C; Moutton S; Venat-Bouvet L; Zattara H; Fricker JP; Gladieff L; Coupier I; ; ; ; Chenevix-Trench G; Hall J; Vincent-Salomon A; Stoppa-Lyonnet D; Andrieu N; Lesueur F Breast Cancer Res; 2018 Apr; 20(1):28. PubMed ID: 29665859 [TBL] [Abstract][Full Text] [Related]
20. The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer. Hjortkjær M; Malik Aagaard Jørgensen M; Waldstrøm M; Ørnskov D; Søgaard-Andersen E; Jakobsen A; Dahl-Steffensen K Int J Gynecol Cancer; 2019 Jan; 29(1):166-173. PubMed ID: 30640700 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]